Russia agrees to produce Sputnik V in India
Hetero and the Russian Direct Investment Fund (RDIF), plan to start the production of vaccine in the beginning of 2021, as per the official statement.
New Delhi, 27/11: Russian Direct Investment Fund(RDIF) and Indian pharma company, Hetero agreed to produce over 100 million doses of Sputnik V in India, according to a statement on the Sputnik V Twitter account on Friday. Sputnik V vaccine is already undergoing Phase II-III trials in India and Dr. Reddy’s Laboratories Ltd. said that it expects late-stage trials of the vaccine to be completed by as early as March 2021.
